source
- UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseasesThe buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.BioPharma Dive · 2mo ago↗ source
- What is your AI drug repurposing strategy missing?Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.BioPharma Dive · 2mo ago↗ source
- UCB bets $2B on Candid's T cell engager ambitionsKen Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is…Endpoints · 2mo ago